Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL116003 | 0.65 | MAPT (0.36) | KDM4EHCRTR1LMNAMAPT | |
| SCHEMBL15136482 | 0.65 | MAPT (0.36) | LMNAMAPT | |
| SCHEMBL11374577 | 0.65 | ALOX15 (0.31) | — | |
| SCHEMBL149345 | 0.64 | TSHR (0.34) | KDM4EHCRTR1LMNAMAPT | |
| SCHEMBL31347802 | 0.62 | KDM1A (0.35) | LMNA | |
| SCHEMBL11093099 | 0.61 | CTSD (0.34) | KDM4ELMNAMAPT | |
| SCHEMBL11176774 | 0.61 | MEN1 (0.32) | KDM4EHCRTR1LMNAMAPT | |
| SCHEMBL10446780 | 0.60 | KDM4E (0.36) | KDM4EHCRTR1LMNAMAPT | |
| SCHEMBL3356415 | 0.60 | KDM4E (0.32) | KDM4EHCRTR1LMNAMAPT | |
| SCHEMBL30599789 | 0.60 | KDM4E (0.32) | KDM4EHCRTR1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003806-B2 | Integrin antagonists useful as anticancer agents | OSI Pharmaceuticals, LLC (US) | 2011-08-23 | — | — | US | claimed |
| EP-1236712-B1 | AMIDINOPHENYLPYRUVIC ACID DERIVATIVE | AJINOMOTO KK (JP) | 2008-08-06 | — | — | EP | claimed |
| EP-1828144-A2 | INTEGRIN ANTAGONISTS USEFUL AS ANTICANCER AGENTS | OSI Pharmaceuticals, Inc. (US) | 2007-09-05 | — | — | EP | claimed |
| US-20060116383-A1 | Integrin antagonists useful as anticancer agents | ALCATEL LUCENT (FR) | 2006-06-01 | — | — | US | claimed |
| WO-2006053342-A2 | INTEGRIN ANTAGONISTS USEFUL AS ANTICANCER AGENTS | OSI PHARMACEUTICALS, INC. (US) | 2006-05-18 | — | — | WO | claimed |
| US-6710056-B2 | PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF HAVE AN EXCELLENT ANTAGONISTIC EFFECT AGAINST ACTIVATED BLOOD COAGULATION FACTOR VII. | AJINOMOTO CO., INC. (JP) | 2004-03-23 | — | — | US | claimed |
| US-20030109547-A1 | Amidinophenylpyruvic acid derivatives | AJINOMOTO CO. INC (JP) | 2003-06-12 | — | — | US | claimed |
| EP-1236712-A1 | AMIDINOPHENYLPYRUVIC ACID DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2002-09-04 | — | — | EP | claimed |
| US-8003806-B2 | Integrin antagonists useful as anticancer agents | OSI Pharmaceuticals, LLC (US) | 2011-08-23 | — | — | US | disclosed |
| EP-1236712-B1 | AMIDINOPHENYLPYRUVIC ACID DERIVATIVE | AJINOMOTO KK (JP) | 2008-08-06 | — | — | EP | disclosed |
| EP-1828144-A2 | INTEGRIN ANTAGONISTS USEFUL AS ANTICANCER AGENTS | OSI Pharmaceuticals, Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20060116383-A1 | Integrin antagonists useful as anticancer agents | ALCATEL LUCENT (FR) | 2006-06-01 | — | — | US | disclosed |
| WO-2006053342-A2 | INTEGRIN ANTAGONISTS USEFUL AS ANTICANCER AGENTS | OSI PHARMACEUTICALS, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| US-6710056-B2 | PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF HAVE AN EXCELLENT ANTAGONISTIC EFFECT AGAINST ACTIVATED BLOOD COAGULATION FACTOR VII. | AJINOMOTO CO., INC. (JP) | 2004-03-23 | — | — | US | disclosed |
| US-20030109547-A1 | Amidinophenylpyruvic acid derivatives | AJINOMOTO CO. INC (JP) | 2003-06-12 | — | — | US | disclosed |
| EP-1236712-A1 | AMIDINOPHENYLPYRUVIC ACID DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2002-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109547-A1 | Amidinophenylpyruvic acid derivatives | HABP2, F2, F7 | KDM4E 2614/4885HCRTR1 4871/4885LMNA 3957/4885 |
| US-20060116383-A1 | Integrin antagonists useful as anticancer agents | ITGB5, ITGA5, ITGB1 | KDM4E 1654/4885HCRTR1 4759/4885LMNA 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.